- Home
- JEF vs INCY Comparison
JEF vs INCY Comparison
Compare JEF & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JEF
- INCY
- Stock Information
- Founded
- JEF 1968
- INCY 1991
- Country
- JEF United States
- INCY United States
- Employees
- JEF N/A
- INCY N/A
- Industry
- JEF Investment Bankers/Brokers/Service
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- JEF Finance
- INCY Health Care
- Exchange
- JEF Nasdaq
- INCY Nasdaq
- Market Cap
- JEF 10.5B
- INCY 17.0B
- IPO Year
- JEF N/A
- INCY 1993
- Fundamental
- Price
- JEF $55.23
- INCY $105.55
- Analyst Decision
- JEF Buy
- INCY Buy
- Analyst Count
- JEF 4
- INCY 19
- Target Price
- JEF $71.00
- INCY $89.19
- AVG Volume (30 Days)
- JEF 2.2M
- INCY 2.8M
- Earning Date
- JEF 09-29-2025
- INCY 10-28-2025
- Dividend Yield
- JEF 2.90%
- INCY N/A
- EPS Growth
- JEF 25.06
- INCY 3878.02
- EPS
- JEF 2.92
- INCY 5.90
- Revenue
- JEF $7,231,501,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- JEF $5.64
- INCY $19.33
- Revenue Next Year
- JEF $10.05
- INCY $10.47
- P/E Ratio
- JEF $18.93
- INCY $17.64
- Revenue Growth
- JEF 15.68
- INCY 18.09
- 52 Week Low
- JEF $39.28
- INCY $53.56
- 52 Week High
- JEF $82.68
- INCY $109.28
- Technical
- Relative Strength Index (RSI)
- JEF 48.47
- INCY 68.24
- Support Level
- JEF $52.09
- INCY $91.16
- Resistance Level
- JEF $59.42
- INCY $109.28
- Average True Range (ATR)
- JEF 1.96
- INCY 4.59
- MACD
- JEF 0.61
- INCY 0.49
- Stochastic Oscillator
- JEF 46.57
- INCY 80.28
About JEF Jefferies Financial Group Inc.
Jefferies is a full-service investment banking and capital markets firm that was founded in 1962. After nearly 30 years of focusing on institutional trading services, it entered the investment banking industry in the early 1990s, which ultimately grew into the core business. In 2013, Jefferies merged with Leucadia, a manufacturing-focused holding company. Since merging, Jefferies became the bedrock of the business as the bulk of the legacy portfolio was sold off and the parent company was renamed to match the subsidiary. Within the investment banking landscape, Jefferies predominately serves the North American middle market and has captured considerable market share over the past decade.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.